FOXO3 and breast carcinoma: Following OSU-53, a novel allosteric adenosine 5′-monophosphate-activated protein kinase (AMPK) activator, for treatment of breast cancer cells, FOXO3a directly binds to the E-cadherin promoter and activates its transcription.